Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025
ALK (ALKB.DC / OMX: ALK B) will publish its results for the first quarter of 2025 in the morning on...
immunotherapy
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly...
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly...
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting
Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune...
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting
Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune...
Immutep Quarterly Activities Report Q3 FY25
Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design...
PredxBio and Hamamatsu Photonics Announce Strategic Partnership to Deliver Next-Generation Spatial Biology Solutions for Cancer Research and Therapeutic Development
PITTSBURGH and BRIDGEWATER, N.J., April 28, 2025 /PRNewswire/ -- PredxBio, a pioneer in AI-powered spatial biomarker discovery, today announced a...
Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting
Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA®...
UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL GABLES, Fla., April 27, 2025...
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3%...
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf...
GenVivo Highlights GEN-1013: A Novel Delivery of an IL-12 Immunotherapy at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GEN-1013 was studied in an aggressive CT26 murine cancer model using both IT and IV administration.Significant tumor reduction was observed...
Symphony Robotics Welcomes Neurosurgery Leader Dr. Neil A. Martin as Chief Medical Officer to Revolutionize Glioblastoma Treatment with First-Ever MRI-Steerable Micro-Robotics
MIAMI, April 25, 2025 /PRNewswire/ -- Symphony Robotics, a pioneer in advanced neurosurgical micro-robotics, today announced the appointment of renowned...
DELFI Diagnostics to Present Early Detection and Advanced Cancer Monitoring Technology Updates at AACR Annual Meeting
Fragmentomics pioneer showcases DELFI-TF treatment monitoring solution alongside early detection capabilities at a premier oncology research event BALTIMORE and PALO...
DELFI Diagnostics to Present Early Detection and Advanced Cancer Monitoring Technology Updates at AACR Annual Meeting
Fragmentomics pioneer showcases DELFI-TF treatment monitoring solution alongside early detection capabilities at a premier oncology research event BALTIMORE and PALO...
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus...
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus...
T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy
– TK-6302, a supercharged PRAME targeting TCR-T therapy, demonstrates best-in-class preclinical anti-tumor efficacy as compared to current clinical stage PRAME...
T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy
– TK-6302, a supercharged PRAME targeting TCR-T therapy, demonstrates best-in-class preclinical anti-tumor efficacy as compared to current clinical stage PRAME...
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable...